AMAALA Appoints HKS Architects Master Planner of Triple Bay and The Coastal Development
17.3.2020 10:00:00 EET | Business Wire | Press release
AMAALA, the ultra-luxury destination located along Saudi Arabia’s northwestern coastline, has announced the appointment of international design firm HKS Architects as Master Planner for Triple Bay and The Coastal Development. Set in the Prince Mohammed bin Salman Nature Reserve, AMAALA will bring to life the desires and ambitions of a community passionate about shaping, and living, transformative moments.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200317005108/en/
The Coastal Development at AMAALA (Photo : AETOSWire)
Commenting on the appointment Chief Executive Officer of AMAALA, Nicholas Naples, said: “AMAALA will be a globally recognised destination for arts and culture, as well as one of the most comprehensive, integrative health, wellness, and sports offerings in the world. In partnership with HKS Architects, we look forward to realising our vision for Triple Bay and The Coastal Development by redefining the best in travel through the creation of transformative personal journeys for the world’s most discerning travellers.”
Triple Bay will offer a fully holistic wellness retreat, state-of-the-art diagnostic medical facilities, and authentic treatments influenced by the local environment and traditional practices. The community will be the first truly integrated sports and entertainment community with diagnostics, medical, and transformative wellness combined with learning in a family friendly environment.
With underwater experiences that will immerse guests directly into the natural domain of dolphins, turtles, and untouched coral reefs, Triple Bay is set to become one of the world’s finest diving destinations in the world.
The Coastal Development is set to become the defining hub of contemporary arts in the Middle East, playing host to a dynamic programme of exciting events from the global arts and cultural calendar. Built on philanthropy, the immersive programmes will be creative, practical, and academic with a strong link to the Saudi community.
The Coastal Development will feature an arts museum and cultural district dedicated to keeping ancient crafts alive, along with an amphitheatre for live performances. This stretch of coastline will be a gathering place for a community of influencers and connoisseurs, complete with premium spa facilities, yoga, meditation, in addition to an equestrian centre equipped to offer rehabilitation, high-tech stabling, tournament-grade polo facilities, and instructors.
Master Planning & Design Principal of HKS Architects, Kevin Underwood, said: “The developments at Triple Bay and The Coastal Development offer a once-in-a-career opportunity to shape a new tourism destination from the beginning and it’s a privilege to be involved as Master Planners. We’re bringing together the global expertise of our firm, using our knowledge of designing for healthcare, sports, and other uses allied to many years’ experience of working with luxury hotels and resorts to create something innovative and contemporary. Sustainability in all aspects is at the heart of our design, seamlessly integrating landscape and buildings with the stunning mountain and marine landscape of the Red Sea.”
AMAALA’s trio of communities – Triple Bay, Coastal Development, and The Island – will represent three different sets of experiences for visitors. The destination’s development will be rolled out in three key phases, with completion slated ahead of the realisation of Saudi Vision 2030.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200317005108/en/
Contact information
Hill+Knowlton
Muneira Al Adwani
Senior Account Executive, +97145539543
muneira.aladwani@hkstrategies.com
AMAALA
Julia Gajcak
Head of Communications and Events, +966532580725
jgajcak@projects.pif.gov.sa
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 17:44:00 EET | Press release
Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the production line. In-Factory Profile Provisioning (IFPP) addresses this challenge by enabling conne
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom